Table 3. Differential severity and clinical management among dengue patients with severe organ involvement outcome compared against matched dengue patients with no severe organ involvement outcome.

	Controls^ (N = 865)	%	Cases (N = 174)	%	AcOR	p-value	95% CI	95% CI
Classification at Presentation
DHF/DSS (WHO 1997)	96	11.1	49	28.2	3.11	<0.0001	2	4.85
WS (WHO 2009)	567	65.6	125	71.8	1.38	0.95	0.95	2.02
Classification as final outcome
DHF/DSS (WHO 1997)	167	19.3	81	46.6	3.95	<0.0001	2.68	5.82
WS (WHO 2009)	656	75.8	152	87.4	1.93	0.008	1.19	3.14
Severe dengue (WHO 2009)	104	12	174	100	62.81	<0.0001	31.37	125.76
Liver involvement	0	0	106	61
Renal involvement	0	0	60	34.5
CNS involvement	0	0	23	13.2
Renal & liver involvement	0	0	15	8.6
Median LOS (IQR)	4	(3–5)	5	(4–7)	1.4	<0.0001	1.27	1.54
ICU admission	0	0	12	6.9
IV Fluid	748	86.5	167	96	3.46	0.003	1.53	7.80
Blood transfusion	4	0.5	10	5.8	11.92	<0.0001	3.55	40.6
Platelets transfusion	80	9.3	58	33.3	5.12	<0.0001	3.21	8.16

DHF - Dengue haemorrhagic fever.

DSS - Dengue shock syndrome.

WS - Dengue warning signs (WHO 2009 dengue classification).

CNS - Central nervous system.

LOS - Length of stay.

IQR - Interquartile range.

ICU - Intensive care unit.

IV - intravenous.

^Matched by year of presentation as the surrogate marker to minimize the impact of different predominant serotypes of that year.

*Adjusted by age group, gender, day post fever duration at presentation, diabetic, hypertension, hyperlipidemia, cardiac disorder and asthma.